Summary: “In an important step toward medical approval, MDMA . . . was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy,” says The New York Times in exclusive coverage published today. “Two months after treatment, 67 percent of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32 percent in the placebo group.”
Soon to be published in Nature Medicine, the first completed MAPS-sponsored Phase 3 clinical trial of MDMA-assisted therapy for PTSD shows positive peer-reviewed results, marking a historic point in the field of psychedelic science.
Read the full article for reflections from researchers and perspectives from study participants.
Originally appearing here.